<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682459</url>
  </required_header>
  <id_info>
    <org_study_id>EXTRA</org_study_id>
    <secondary_id>2015-003884-12</secondary_id>
    <nct_id>NCT02682459</nct_id>
  </id_info>
  <brief_title>ACE-inhibitors in Extracapillary Glomerulonephritis</brief_title>
  <acronym>EXTRA</acronym>
  <official_title>A Pilot, Prospective, Randomized, Open-label, Blinded Endpoint (Probe) Histopathology Trial to Assess the Effects of ACE- Inhibition Therapy on Glomerular Proliferative Lesions in Patients With Extracapillary Glomerulonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monia Lorini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Di Ricerche Farmacologiche Mario Negri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The natural course of extracapillary glomerulonephritis is severe leading to End-Stage Renal
      Disease (ESRD) or death in most cases. Despite immunosuppressive treatment, long-term renal
      outcome remains poor since active crescents usually progress to fibrotic scars with
      glomerular occlusion and disruption.In experimental models Angiotensin Converting Enzyme
      (ACE)-inhibitor therapy targeting the over-expression of angiotensin type 1 (AT1) receptors,
      that are responsible for dysregulated proliferation of parietal cell progenitors, blocks the
      formation of crescents and their fibrotic evolution. Should these drugs have similar effects
      in humans, ACE-inhibitor therapy on top of standard immunosuppression might be instrumental
      to prevent ESRD and promote renal function recovery in clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The extent of extracapillary proliferation on light microscopy, measured as % of total glomeruli with proliferative lesions at post-treatment repeat biopsy.</measure>
    <time_frame>Changes from baseline and 6 and 18 month.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of parietal cell proliferation markers at glomerular level, graded on a scale of 0 to 3 (0: no staining, 1: mild, 2: moderate, 3: strong diffuse</measure>
    <time_frame>Changes from baseline and 6 and 18 month.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fibrosclerotic crescents</measure>
    <time_frame>Changes from baseline and 6 and 18 month.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR) measured by iohexol plasma clearance</measure>
    <time_frame>Changes from baseline and 6, 12 and 18 month.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Extracapillary Glomerulonephritis</condition>
  <arm_group>
    <arm_group_label>Lisinopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive, in addition to standard immunosuppressive therapy, lisinopril starting with 5 mg/day, then progressively up-titrated to reach the maximum tolerable dose (target dose) for 18 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive only the standard immunosuppressive therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <arm_group_label>Lisinopril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rapidly progressive renal failure associated with acute nephritic syndrome and/or
             nephrotic syndrome;

          -  Histology evidence of extracapillary proliferation with less than 50% of sclerotic
             glomeruli and associated with:

               1. Type I: Anti-Glomerular Basement Membrane (GBM) antibody glomerulonephritis,

               2. Type II: Pauci-immune vasculitis or Anti Neutrophil Cytoplasmic Antibody (ANCA)
                  associated vasculitis;

               3. Type III: Immune-complex mediated glomerular diseases: Proliferative lupus
                  nephritis (LN), IgA nephropathy (IgAN)/ Schönlein-Henoch purpura, Type I
                  membranoproliferative glomerulonephropathy (MPGN), Primary or secondary
                  membranous nephropathy (MN), Primary or idiopathic immune complex
                  glomerulonephritis.

          -  Clinical indication to immunosuppressive therapy;

          -  No specific indication to treatment with Renin Angiotensin System (RAS) inhibitors
             such as heart failure or coronary ischemic disease;

          -  Written informed consent.

        Exclusion Criteria:

          -  Pre-existing advanced chronic renal failure (creatinine clearance less than 20
             ml/min/1.73m2);

          -  Evidence of B or C virus active infection;

          -  HIV infection;

          -  Recent diagnosis of malignancy;

          -  Prolonged bleeding time and any other contraindication to kidney biopsy evaluation;

          -  Any specific contraindication to ACE inhibitor therapy (that is: history of angioedema
             or other treatment-related serious adverse events);

          -  Pregnancy or lactating;

          -  Women of childbearing potential without following a scientifically accepted form of
             contraception;

          -  Inability to understand the risks and benefit of the study or evidence of an
             uncooperative attitude;

          -  Legal incapacity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barbara Ruggiero, MD</last_name>
    <phone>0039 035 45351</phone>
    <email>barbara.ruggiero@marionegri.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ettore Sabadini, MD</last_name>
    <email>esabadini@asst-pg23.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò</name>
      <address>
        <city>Ranica</city>
        <state>Bergamo</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Barbara Ruggiero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giuseppe Remuzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ettore Sabadini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piero Ruggenenti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hruskova Z, Honsova E, Berden AE, Rychlik I, Lanska V, Zabka J, Bajema IM, Tesar V. Repeat protocol renal biopsy in ANCA-associated renal vasculitis. Nephrol Dial Transplant. 2014 Sep;29(9):1728-32. doi: 10.1093/ndt/gfu042. Epub 2014 Feb 26.</citation>
    <PMID>24578468</PMID>
  </reference>
  <reference>
    <citation>Smeets B, Angelotti ML, Rizzo P, Dijkman H, Lazzeri E, Mooren F, Ballerini L, Parente E, Sagrinati C, Mazzinghi B, Ronconi E, Becherucci F, Benigni A, Steenbergen E, Lasagni L, Remuzzi G, Wetzels J, Romagnani P. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol. 2009 Dec;20(12):2593-603. doi: 10.1681/ASN.2009020132. Epub 2009 Oct 29.</citation>
    <PMID>19875807</PMID>
  </reference>
  <reference>
    <citation>Benigni A, Morigi M, Rizzo P, Gagliardini E, Rota C, Abbate M, Ghezzi S, Remuzzi A, Remuzzi G. Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. Am J Pathol. 2011 Aug;179(2):628-38. doi: 10.1016/j.ajpath.2011.04.003. Epub 2011 Jun 2.</citation>
    <PMID>21718676</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>A.O. Ospedale Papa Giovanni XXIII</investigator_affiliation>
    <investigator_full_name>Monia Lorini</investigator_full_name>
    <investigator_title>EC Secretary</investigator_title>
  </responsible_party>
  <keyword>Extracapillary glomerulonephritis</keyword>
  <keyword>crescentic glomerulonephritis</keyword>
  <keyword>rapidly progressive renal failure</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>ACE-inhibitors</keyword>
  <keyword>fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

